Ascletis Pharma at ObesityWeek 2026

Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website

Ascletis Pharma brings 2 presentations to ObesityWeek 2026 in National Harbor. Its sessions present preclinical work on obesity drug candidates. One studies the oral small molecule GIPR agonist ASC48 in vitro and in vivo, and another reports a longer half-life for ASC37 than retatrutide in nonhuman primates and marked weight loss in DIO mice.

OrganizationObesityWeek 2026 Attendance
Ascletis Pharma
Hangzhou, China
Biotech
Biotech developing oral and long-acting peptide candidates for obesity, including ASC37 and ASC48.
Poster
Sat Nov 14
7:30pm–8:30pm
Poster
Sat Nov 14
7:30pm–8:30pm
Oral Small Molecule GIPR Agonist ASC48 for Obesity: In Vitro and In Vivo Studies
Obesity pharmacotherapy and drug developmentMetabolism and integrative physiology

Explore the full ObesityWeek 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in National Harbor. Leave your work email and we’ll be in touch.

Privacy

Download the full ObesityWeek 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Ascletis Pharma

Tell us what you sell and we’ll find the people at Ascletis Pharma most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction